From generative artificial intelligence (GenAl), augmented reality (AR), and virtual reality (VR) to decentralised clinical trials and 3D printing, we delve into the latest tech trends such Cellular Multi-Omics, Gene Editing CRISPR Technologies, Decentralised Clinical Trial (DCTs), digital health, digital twins, smart manufacturing, and wearables poised to lead the life sciences landscape in 2024.
As we enter 2024, we predict the technology trends that will influence the life sciences industry in the upcoming year. The evolution of GenAI is poised to revolutionise healthcare, with 49.6 per cent of healthcare providers planning to invest in GenAI use cases, as per a recent IDC report. Augmented Reality (AR) and Virtual Reality (VR) applications are gaining traction for enhancing medical training and surgeries. Trends such as 3D printing, Cellular Multi-Omics, Gene Editing CRISPR Technologies, Decentralised Clinical Trial (DCTs), digital health, digital twins, smart manufacturing, and wearables are expected to redefine the landscape in the new year. Let's delve into these trends in detail.
Gene Editing CRISPR Technologies propel cell and gene therapies
On December 8, 2023, the US FDA (United States Food and Drug Administration) approved the firstever CRISPR-based treatment, CASGEVY, for sickle cell disease by Vertex and CRISPR Therapeutics. This marks a pivotal moment in gene editing, offering hope for genetic disorders and fueling the CRISPR therapeutics sector, one of pharma's buzziest areas.
"In the dynamic realm of gene editing and CRISPR technologies, the pace of advancement is nothing short of remarkable. Developers in the cell and gene therapy arena are fervently working to create improved therapies characterised by greater efficacy, improved safety profiles, and streamlined manufacturing processes. At the heart of this pursuit lie innovations in payload and delivery mechanisms.
This story is from the BioSpectrum Asia January 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia January 2024 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
